U.S., Nov. 20 -- ClinicalTrials.gov registry received information related to the study (NCT07947940) titled 'Assessing Prognostic Value of Markers of Cardiac Disease Progression in ATTR-CM Patients Treated With Tafamidis' on Nov. 13.

Brief Summary: This study aims to assess the prognostic utility of various markers of disease progression among patients diagnosed with ATTR-CM treated with tafamidis utilizing Truveta database in the US. We will evaluate the impact of markers of disease progression (such as eGFR, ODI, NT-proBNP, NYHA and KCCQ) at Month 12 after initiation of tafamidis on clinical outcomes (including all-cause mortality, CV-related mortality, first CV hospitalization) among ATTR-CM patients treated with tafamidis in the US.

S...